Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
Carboplatin and paclitaxel as doublet are the standard therapeutic option for advanced stage ovarian carcinoma in the first line as well as relapse. Carboplatin with its better toxicity profile has replaced cisplatin as the first line drug. However, increase in incidence of carboplatin hypersensitiv...
Main Authors: | , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Medknow Publications & Media Pvt Ltd
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080656/ |